Thus, we suggest that the utility of NRG1 as a predictive biomarker to anti-HER3 therapies in luminal breast cancer may be provided by the stromal compartment, while analysis of bulk tumour tissues may dilute its detection [57]. The gene discussed is ERBB3; the disease is breast cancer.